LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (OTCBB: PBYI), a development stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2012. For the quarter ended June 30, 2012, Puma reported a net loss applicable to common stock of $14.8 million, or $0.74 per share. Net loss applicable to common stock for the six months ended June 30, 2012, was $26.6 million, or $1.33 per share.
